References
- MHLW. Guideline for ensuring the quality, safety, and efficacy of biosimilars. 2020 [cited 2024 Mar 30]. Available from: https://www.pmda.go.jp/files/000267479.pdf
- US FDA. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015 [cited 2024 Jan 3]. Available from: https://www.fda.gov/media/82647/download
- EMA. Guideline on similar biological medicinal products (CHMP/437/04 Rev 1). 2014 [cited 2024 Jan 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
- EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues. 2015 [cited 2024 Jan 3]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf
- MHLW. Questions and answers (Q&A) regarding the guideline for the quality, safety, and efficacy assurance of biosimilars. 2020 [cited 2024 Jan 3]. Available from: http://www.nihs.go.jp/dbcb/TEXT/Q&A_0204_1.pdf
- PMDA. Search for pharmaceutical medicine information. [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuSearch
- Kuribayashi R, Nakano A, Hariu A, et al. Historical overview of regulatory approvals and PMDA assessments for biosimilar products in Japan during 2009–2022. BioDrugs. 2023;37(4):443–451. doi: 10.1007/s40259-023-00605-6
- PMDA. Review report for infliximab BS IV infusion [NK] and [CTH]. 2014 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2014/P201400086/530191000_22600AMX00758_A100_1.pdf
- Takeuchi T, Yamanaka H, Tanaka Y, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25(6):817–824. doi: 10.3109/14397595.2015.1022297
- PMDA. Review report for infliximab BS IV infusion [Ayumi] and [Nichiiko]. 2017 [cited 2024 Jan 3]. https://www.pmda.go.jp/drugs/2014/P201400086/530191000_22600AMX00758_A100_1.pdf
- PMDA. Review report for infliximab BS IV infusion. Pfizer; 2018 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2018/P20180604002/671450000_23000AMX00482000_A100_1.pdf
- Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20(1):155. doi: 10.1186/s13075-018-1646-4
- PMDA. Review report for rituximab BS IV infusion [KHK]. 2017 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2017/P20171024002/270428000_22900AMX00970_A100_3.pdf
- Jurczak W, Moreira I, Kanakasetty GB, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350–e361. doi: 10.1016/S2352-3026(17)30106-0
- PMDA. Review report for rituximab BS IV infusion. Pfizer; 2019 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2019/P20190918002/671450000_30100AMX00259_A100_1.pdf
- Sharman JP, Liberati AM, Ishizawa K, et al. A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL). BioDrugs. 2020;34(2):171–181. doi: 10.1007/s40259-019-00398-7
- PMDA. Review report for etanercept BS SC injection [MA]. 2018 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2018/P20180207002/790005000_23000AMX00005_A100_1.pdf
- Matsuno H, Tomomitsu M, Hagino A, et al. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis. 2018;77(4):488–494. doi: 10.1136/annrheumdis-2017-212172
- PMDA. Review report for etanercept BS SC injection [TY] and [Nichiiko]. 2019 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2019/P20190226001/890640000_23100AMX00304_A100_1.pdf
- Yamanaka H, Kamatani N, Tanaka Y, et al. A comparative study to assess the efficacy, safety, and immunogenicity of YLB113 and the etanercept reference product for the treatment of patients with rheumatoid arthritis. Rheumatol Ther. 2020;7(1):149–163. doi: 10.1007/s40744-019-00186-3
- PMDA. Review report for trastuzumab BS IV infusion [NK] and [CTH]. 2018 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2018/P20180314003/530191000_5122908013560_A100_1.pdf
- Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017;18(7):917–928. doi: 10.1016/S1470-2045(17)30434-5
- PMDA. Review report for trastuzumab BS IV infusion [Daiichi Sankyo]. 2018 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2018/P20181017001/430574000_23000AMX00802_A100_2.pdf
- Hanes V, Chow V, Zhang N, et al. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol. 2017;79(5):881–888. doi: 10.1007/s00280-017-3286-9
- PMDA. Review report for trastuzumab BS IV infusion. Pfizer; 2018 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2018/P20181012001/671450000_23000AMX00800_A100_1.pdf
- Pegram MD, Bondarenko I, Zorzetto MMC, et al. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. Br J Cancer. 2019;120(2):172–182. doi: 10.1038/s41416-018-0340-2
- PMDA. Review report for bevacizumab BS IV infusion. Pfizer; 2019 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2019/P20190524001/671450000_30100AMX00023_A100_2.pdf
- Reinmuth N, Bryl M, Bondarenko I, et al. PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin®), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study. BioDrugs. 2019;33(5):555–570. doi: 10.1007/s40259-019-00363-4
- PMDA. Review report for bevacizumab BS IV infusion [Daiichi Sankyo]. 2019 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2019/P20191003001/430574000_30100AMX00289_A100_1.pdf
- Hanes V, Chow V, Pan Z, et al. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects. Cancer Chemother Pharmacol. 2018;82(5):899–905. doi: 10.1007/s00280-018-3695-4
- PMDA. Review report for bevacizumab BS IV infusion [Nichiiko]. 2022 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2021/P20211223003/530169000_30400AMX00004_A100_1.pdf
- Eto T, Karasuyama Y, González V, et al. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers. Cancer Chemother Pharmacol. 2021;88(4):713–722. doi: 10.1007/s00280-021-04324-z
- PMDA. Review report for bevacizumab BS IV infusion [CTNK]. 2022 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2022/P20221004002/530191000_30400AMX00418_A100_1.pdf
- Verschraegen C, Andric Z, Moiseenko F, et al. Candidate bevacizumab biosimilar CT-P16 versus European Union reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer: a randomized controlled trial. BioDrugs. 2022;36(6):749–760. doi: 10.1007/s40259-022-00552-8
- PMDA. Review report for adalimumab BS SC injection [FKB]. 2020 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2020/P20200624002/230971000_30200AMX00466_A100_1.pdf
- Yonemura T, Yazawa R, Haranaka M, et al. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants. BMC Pharmacol Toxicol. 2022;23(1):6. doi: 10.1186/s40360-021-00545-3
- PMDA. Review report for adalimumab BS SC injection [Daiichi Sankyo]. 2021 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2021/P20210122001/430574000_30300AMX00017_A100_2.pdf
- PMDA. Review report for adalimumab BS SC injection [MA]. 2021 [cited 2023 Oct 15]. Available from: https://www.pmda.go.jp/drugs/2021/P20210324004/790005000_30300AMX00236_A100_1.pdf
- Matsuno H, Kang YM, Okada M, et al. Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study. Clin Exp Rheumatol. 2022;40(5):1025–1033. doi: 10.55563/clinexprheumatol/cyudn8
- PMDA. Review report for adalimumab BS SC injection [CTNK]. 2023 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2023/P20231010001/530191000_30500AMX00239_A100_1.pdf
- Haranaka M, Tanaka T, Kim S, et al. Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Immunotherapy. 2023;15(3):149–161. doi: 10.2217/imt-2022-0181
- PMDA. Review report for ranibizumab BS ITV injection [Senju]. 2021 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2021/P20210909002/380086000_30100AMX00243_A100_1.pdf
- PMDA. Review report for ustekinumab BS SC injection [F]. 2023 [cited 2024 Jan 3]. Available from: https://www.pmda.go.jp/drugs/2023/P20230915001/670109000_30500AMX00238_A100_1.pdf
- Wynne C, Hamilton P, McLendon K, et al. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults. Expert Opin Investig Drugs. 2023;32(5):417–427. doi: 10.1080/13543784.2023.2215426
- Clinicaltrials.Gov. A study of PF-06438179 (infliximab-Pfizer) and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis (reflections B537-02). ClinicalTrials.gov; [cited 2024 Jan 3]. Available from: https://clinicaltrials.gov/study/NCT02222493?term=PF-06438179&rank=2
- Clinicaltrials.Gov. A GP2013 in the treatment of patients with previously untreated, advanced stage follicular lymphoma. (ASSIST_FL). ClinicalTrials.gov; [cited 2024 Jan 3]. Available from: https://clinicaltrials.gov/study/NCT01419665?term=follicular%20lymphoma%20,%20rituximab,sandoz&rank=1
- Clinicaltrials.Gov. A study of PF-05280586 (rituximab-Pfizer) or MabThera® (rituximab-EU) for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma (reflections B328-06). ClinicalTrials.gov; [cited 2024 Jan 3]. Available from: https://clinicaltrials.gov/study/NCT02213263?term=PF-05280586&rank=2
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612. doi: 10.1136/annrheumdis-2012-203091
- Park W, Lee SJ, Yun J, et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, phase I study. Expert Rev Clin Immunol. 2015;11(suppl 1):S25–S31. doi: 10.1586/1744666X.2015.1090311
- Shennak M, Al-Jaouni R, Kshirasagar S, et al. An open-label, randomized, single-dose, crossover, comparative pharmacokinetics study of YLB113 and the etanercept reference product in healthy adult male subjects. Eur J Drug Metab Pharmacokinet. 2020;45(4):467–475. doi: 10.1007/s13318-020-00613-9
- Markus R, Chow V, Pan Z, et al. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men. Cancer Chemother Pharmacol. 2017;80(4):755–763. doi: 10.1007/s00280-017-3416-4
- Sinn A, García-Alvarado F, Gonzalez V, et al. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. Br J Clin Pharmacol. 2022;88(3):1063–1073. doi: 10.1111/bcp.15032
- Cho SH, Han S, Ghim JL, et al. A randomized, double-blind trial comparing the pharmacokinetics of CT-P16, a candidate bevacizumab biosimilar, with its reference product in healthy adult males. BioDrugs. 2019;33(2):173–181. doi: 10.1007/s40259-019-00340-x
- Puri A, Niewiarowski A, Arai Y, et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects. Br J Clin Pharmacol. 2017;83(7):1405–1415. doi: 10.1111/bcp.13245
- Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis. 2017;76(3):526–533. doi: 10.1136/annrheumdis-2015-208914
- Yu KS, Jang IJ, Lim HS, et al. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: a randomized phase I study in healthy subjects. Clin Transl Sci. 2021;14(4):1280–1291. doi: 10.1111/cts.12967
- Chiba K, Yoshitsugu H, Kyosaka Y, et al. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed? J Clin Pharmacol. 2014;54(5):483–494. doi: 10.1002/jcph.231
- Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558. doi: 10.1038/clpt.2008.170
- Thomas VA, Balthasar JP. Understanding inter-individual variability in monoclonal antibody disposition. Antibodies (Basel). 2019;8(4):56. doi: 10.3390/antib8040056
- Matsushima S, Huang Y, Suzuki H, et al. Ethnic sensitivity assessment - pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs. Expert Opin Drug Metab Toxicol. 2015;11(2):179–191. doi: 10.1517/17425255.2015.990438
- Willen D, Uhl W, Wolna P, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of atacicept in a randomized trial in healthy Caucasian and Japanese subjects. Eur J Drug Metab Pharmacokinet. 2020;45(1):27–40. doi: 10.1007/s13318-019-00575-7
- Kawai S, Sekino H, Yamashita N, et al. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol. 2006;46(4):418–423. doi: 10.1177/0091270006286435
- Zhao L, Ren TH, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin. 2012;33(11):1339–1347. doi: 10.1038/aps.2012.51
- MHLW. Q&A for basic principles for conducting phase 1 studies in Japanese prior to initiating multi-regional clinical trials including Japan for drugs in which early clinical development is preceding outside Japan. 2023 [cited 2024 Jan 4]. Available from: https://www.mhlw.go.jp/hourei/doc/tsuchi/T231226I0030.pdf
- MHLW. Guideline for bioequivalence studies of generic products Q & a. 2020 [cited 2024 Jan 4]. Available from: https://www.nihs.go.jp/drug/be-guide(e)/2020/QA1_BE_2020.pdf
- Kuribayashi R, Yamaguchi T, Takagi K. Modernization and strengthening of bioequivalence guidelines in Japan. Clin Pharmacokinet. 2021;60(2):145–151. doi: 10.1007/s40262-020-00965-0
- Athalye SN, Baruah DB, Mittra S, et al. Ethnic sensitivity assessments in biosimilar monoclonal antibodies clinical development programmes: necessary or not? Generics Biosimilars Initiat J (GaBI J). 2023;12(2):61–66.
- MHLW. Questions and answers (Q&A) on guideline for ensuring the quality, safety, and efficacy of biosimilars. 2024 [cited 2024 Mar 30]. Available from: https://www.pmda.go.jp/files/000267480.pdf
- ICH E5 (R1). Ethnic factors in the acceptability of foreign clinical data. 1998 [cited 2024 Jan 4]. Available from: https://www.pmda.go.jp/files/000156836.pdf
- PMDA. Consultations. Available from: https://www.pmda.go.jp/english/review-services/consultations/0002.html
- PMDA. Review report for somatropin BS SC injection. Sandoz; 2009 [cited 2024 Mar 14]. Available from: https://www.pmda.go.jp/drugs/2009/P200900093/270428000_22100AMX01031000_A100_2.pdf